All In Biotech

Drug Trial Radar · NCT03422822

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

A PHASE 3 MULTI-CENTER, LONG-TERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB, WITH OR WITHOUT TOPICAL MEDICATIONS, ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,166 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,166

Actual

Start

Mar 8, 2018

Primary completion

Dec 22, 2025

Study completion Dec 22, 2025

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Feb 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to severe atopic dermatitis and have completed a qualifying parent study. The efficacy and safety of two dosage strengths of Abrocitinib, 100 mg and 200 mg taken orally once daily, will be evaluated over variable lengths of study participation. The study consists of a 92 week initial treatment period followed by a variable length secondary treatment period during which subjects will receive treatment with open-label abrocitinib until availability of commercial product in their country, or until the sponsor terminates the study in that country. The B7451015 study also includes a sub-study evaluating whether abrocitinib has any potential effects on adolescent bone with regard to abnormal bone findings in knee MRI. The sub-study will be conducted in selected countries at selected sites. Eligible subjects are those who were 12 to \<18 years of age at the screening visit of the qualifying parent study and who are currently participating in the main B7451015 study. The sub-study will include serial Magnetic Resonance Imaging (MRI) annually and continue until all enrolled subjects are 18 years of age and have been imaged at least once or have discontinued/withdrawn.

Conditions

  • Dermatitis, Atopic

Interventions

  • Abrocitinib 100 mgDrug

    In the initial treatment period, Abrocitinib 100 mg, administered as two tablets to be taken orally once daily.

  • Abrocitinib 200 mgDrug

    In the initial treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.

  • PlaceboDrug

    For subjects whose dose was changed from 100 mg Abrocitinib to placebo, one tablet will be administered to be taken orally once daily for the remainder of the study.

  • Abrocitinib 100 mgDrug

    For subjects whose dose was changed from 200 mg Abrocitinib to 100 mg PF-04965842, one tablet will be administered to be taken orally once daily for the remainder of the study.

  • Abrocitinib 100 mgDrug

    In the secondary treatment period, Abrocitinib 100 mg, administered as one tablet to be taken orally once daily.

  • Abrocitinib 200 mgDrug

    In the secondary treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment emergent adverse eventsTime frame: Throughout study regardless of availability of commercial product until at least 2024, or until the sponsor terminates the study; an estimated maximum of 8 years
  2. Serious adverse events and adverse events leading to discontinuationTime frame: Throughout study regardless of availability of commercial product until at least 2024, or until the sponsor terminates the study; an estimated maximum of 8 years
  3. Change from baseline in clinical laboratory valuesTime frame: Throughout study regardless of availability of commercial product until at least 2024, or until the sponsor terminates the study; an estimated maximum of 8 years
  4. Change from baseline in electrocardiogram (ECG) measurementsTime frame: Throughout study regardless of availability of commercial product until at least 2024, or until the sponsor terminates the study; an estimated maximum of 8 years
  5. Change from baseline in vital signsTime frame: Throughout study regardless of availability of commercial product until at least 2024, or until the sponsor terminates the study; an estimated maximum of 8 years

Locations

539 sites in 28 countries. Site status is shown where the registry gives one.

  • Total Skin and Beauty Dermatology Center, PC

    Birmingham, Alabama

  • Clinical Research Center of Alabama, LLC

    Birmingham, Alabama

  • University of Alabama at Birmingham - Dermatology Research Clinic

    Birmingham, Alabama

  • University of Alabama at Birmingham Hospital Outreach Lab

    Birmingham, Alabama

  • Clinical Research Center of Alabama, LLC

    Birmingham, Alabama

  • The University of Alabama at Birmingham, Department of Dermatology

    Birmingham, Alabama

  • Emmaus Research Center, Inc.

    Anaheim, California

  • California Dermatology & Clinical Research Institute

    Encinitas, California

  • First OC Dermatology Research Inc

    Fountain Valley, California

  • Marvel Research, LLC

    Huntington Beach, California

  • Tilda Research Inc.

    Irvine, California

  • Beach Allergy and Asthma Specialty Group, A Medical Corporation

    Long Beach, California

  • Keck School of Medicine of University of Southern California

    Los Angeles, California

  • Wallace Medical Group, Inc

    Los Angeles, California

  • Allergy & Asthma Associates of Southern California dba Southern California Research

    Mission Viejo, California

  • Dermatology Specialists, Inc.

    Oceanside, California

  • Peninsula Headlands LLC

    Rolling Hills Estates, California

  • UC Davis Health

    Sacramento, California

  • MedDerm Associates

    San Diego, California

  • University of California San Diego Dermatology

    San Diego, California

  • Synergy Dermatology

    San Francisco, California

  • San Luis Dermatology and Laser Clinic

    San Luis Obispo, California

  • Southern California Dermatology, Inc.

    Santa Ana, California

  • Wolverine Clinical Trials, Llc

    Santa Ana, California

  • Mosaic Dermatology

    Santa Monica, California

  • Clinical Science Institute

    Santa Monica, California

  • Asthma and Allergy Associates, PC

    Colorado Springs, Colorado

  • Colorado Springs Dermatology Clinic, PC

    Colorado Springs, Colorado

  • Skin Care Research

    Boca Raton, Florida

  • Renaissance Research and Medical Group, Inc

    Cape Coral, Florida

  • Florida Academic Centers Research and Education, LLC

    Coral Gables, Florida

  • Skin Research Institute

    Coral Gables, Florida

  • Moonshine Research Center, Inc.

    Doral, Florida

  • Homestead Research Institute

    Homestead, Florida

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida

  • Solutions Through Advanced Research, Inc.

    Jacksonville, Florida

  • C & R Research Services USA, Inc

    Kendall, Florida

  • Clinical Trials Solutions

    Miami, Florida

  • Global Health Clinical Trials Corp

    Miami, Florida

  • Baumann Cosmetic and Research Institute

    Miami, Florida

Showing 40 of 539 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.